Repatha Shows Promising Activity against Low-Density Lipoprotein Cholesterol and Cardiovascular Events

Release Date: 09-Aug-2020

Metabolic syndromes in today’s generation has been widely observed and diagnosed. An important reason for such high cases of metabolic syndromes in the population is the unhealthy lifestyle that is getting attached to the upbringing. This is a major conern across the globe and now this has been focused by several researchers in order to slow down the progress of metabolic disorders such as LDL-Cholesterol and cardiovascular diseases. According to a group of researchers who were conducting research regarding the same, evolocumab (Repatha), a drug is effective against reducing the level of low-density lipoprotein cholesterol (LDL-C) and the risk of cardiovascular (CV) events.

It was found through the course of the study that evolocumab was effective in reducing the level of cardiovascular risk in the patients who are suffering from metabolic syndrome as well as without any metabolic syndrome. Also, it was found that the patients who were suffering from the syndrome without diabetes also showed greater risk reduction with evolocumab. It was evaluated through a trial that included 27,432 patients with atherosclerotic CV disease. The drug was given to the enrolled patients subcuataneously. 

The aim of the trial was to composite and assess CV death, myocardial infarction (MI), stroke, coronary revascularization, or hospitalization. It was found that the absolute risk reduction with the drug in the patients with metabolic syndrome and diabetes was 2.1% and 4.9% in 4.9% in non-syndrome patients with diabetes; 2.5% in patients with metabolic syndrome and no diabetes; and 0.9% in patients with neither. It was suggested from the clinical trial that the patients who were suffering from atherosclerotic CV disease and diabetes as well as metabolic syndrome patients without diabetes received more beneficial outcomes from drug therapy.